This book integrates a science and business approach to provide an introduction and an insider view of intellectual property issues within the biotech industry, with case studies and examples from developing economy markets. Broad in scope, this book covers key principles in pharmaceutical, industrial, and agricultural biotechnology within four parts. Part 1 details the principles of intellectual property and biotechnology. Part 2 covers plant biotechnology, including biotic and abiotic st...

Cancer threatens the lives of people around the world. Women, in particular, are at risk of certain cancers with a genetic cause. Certain mutations in the BRCA1 and BRCA2 genes put mothers and daughters at risk of breast and ovarian cancers. Unlike many cancers that most commonly occur after age 60, these inheritable cancers threaten women’s lives, health and fertility even when they are young, before most would even begin to go for annual mammogram screenings to check for breast cancer.

Conventional plant breeding alone can no longer sustain the rising global demand for food. Genetic engineering technology makes it possible to develop new crop varieties with improved yield performance, specific quality attributes (external and internal in vegetable crops), resistance to diseases and insect pests, and environmental stresses. Genetic engineering technology for developing GM crops is complementary to genome editing and other breeding technologies. In addition to food require...

Explores current and emerging applications of microbes as cancer-fighting agentsWILEY SERIES IN BIOTECHNOLOGY AND BIOENGINEERINGAnurag S. Rathore, Series EditorToday, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. In recent years, researc...

This book deals with the emerging concept that certain pathogenic bacteria and viruses, when infecting people with cancer, actively fight tumors, allowing their regression. Although such observations go back more than 100 years, use of specific bacterial strains, or viruses, usually genetically modified with known anticancer drugs, and their protein/peptide products, has gained ground in recent years, allowing significant cancer regression in clinical trials with stage III/IV cancer patien...